Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical stage global biopharmaceutical company that develops and delivers ...

Structure Therapeutics' (GPCR) subsidiary Gasherbrum Bio signed a patent license agreement with Genentech, granting Genentech ...

Global g-protein coupled receptors (GPCRs) market growth is Driven by Rising drug discovery activities, expanding applications in targeted therapeutics, and increasing prevalence of chronic and ...

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has issued an update. On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure ...

Structure Therapeutics, through its subsidiary Gasherbrum, entered into a non-exclusive patent license with Genentech, the US ...

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew ...

Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln, ...

Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Explore how peptide drugs are changing the hundred-billion-level weight loss market, and how this landscape is changing as ...

Four researchers at Johannes Gutenberg University Mainz (JGU) have been awarded prestigious ERC Consolidator Grants by the European Research Council ...